A Phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with NAMD Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-AMD-303 study